Tarsus Pharmaceuticals Inc (TARS) is a Healthcare · Biotechnology company listed on NASDAQ. Price $78.09 (-1.19%), Market cap $2.79B, 52-week low–high $38.82 ~ $82.51.
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites. It sells its products to specialty pharmacies and distributors, as well as clinics, hospitals, pharmacies, and federal healthcare programs. The company also develops TP-04, a sterile aqueous gel formulation of lotilaner in Phase 2 trial for the treatment of ocular rosacea; and TP-05, an oral tablet formulation of lotilaner in Phase 2 trial for the prevention of Lyme d
Financial statements, price targets, institutional (13F) holdings and related news for Tarsus Pharmaceuticals Inc are updated in real time on BlackAll Trade.
Tarsus Pharmaceuticals Inc trades at $78.09 (-1.19%). Real-time quotes and charts are available on BlackAll Trade.
Tarsus Pharmaceuticals Inc has a market cap of about $2.79B.
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company of